Abstract: The present invention makes available methods and reagents for inducing activation of a hedgehog pathway in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as a small molecule, in a sufficient amount to achieve a therapeutic result. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
January 27, 2004
Assignee:
Curis, Inc.
Inventors:
Anthony David Baxter, Edward Andrew Boyd, Oivin M. Guicherit, Jeffrey Porter, Stephen Price, Lee Rubin
Abstract: The present invention relates to morphogen analogs, particularly analogs of a BMP, such as OP-1, that are agonists or antagonists of a BMP, such as OP-1, biological activity.
Type:
Application
Filed:
June 6, 2002
Publication date:
October 2, 2003
Applicant:
Curis, Inc.
Inventors:
Peter C. Keck, Dattatreyamurty Bosukonda
Abstract: Anti-hedgehog antibodies directed at blocking the binding of hedgehog to its receptor patched-1, will impair lipid metabolism and storage. This invention presents methods for the treatment of a variety of lipid metabolism and lipid storage disorders, aberrant apolipoprotein expression, atherosclerosis and other lipid associated disorders using lipid modulators such as hedgehog antagonists or hedgehog agonists.
Abstract: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
September 2, 2003
Assignee:
Curis, Inc.
Inventors:
Jeffrey Porter, Oivin M. Guicherit, Lee Rubin, Anthony David Baxter, Edward Andrew Boyd, Stephen Price
Abstract: The present invention relates to the discovery of a new member of the hedgehog receptor family, referred to herein as human ptc-2 (for patched-2 protein). The human ptc-2 polypeptides of the present invention include polypeptides which bind the products of the hedgehog gene family. Hedgehog family members are known for their broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, both adult and embryonic, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
Abstract: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.
Type:
Application
Filed:
September 17, 2002
Publication date:
July 24, 2003
Applicant:
Curis, Inc.
Inventors:
Anthony David Baxter, Edward Andrew Boyd, Maria Frank-Kamenetsky, Oivin Guicherit, Jeffery Porter, Stephen Price, Lee Rubin, John Harry Alexander Stibbard
Abstract: Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.
Type:
Application
Filed:
April 12, 2002
Publication date:
June 5, 2003
Applicant:
Curis, Inc.
Inventors:
William K. Jones, Ronald F. Tucker, David C. Rueger, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath
Abstract: The invention provides methods, compositions and devices for inducing tissue-specific regeneration in a mammal, or for stimulating proliferation of mammalian progenitor cells. The present methods, compositions and devices make use of osteogenic protein 1 (OP-1), which is appreciated herein as a tissue morphogen, i.e., a substance competent to induce tissue-specific morphogenesis of mammalian body tissues in addition to bone and/or cartilage. Alternatively, the present methods, compositions and devices make use of other naturally-occurring or biosynthetic proteins sharing a defined structural and functional relationship with OP-1 and thus appreciated herein also to function as tissue morphogens. Optionally, OP-1 or a related protein can be used alone or when adsorbed on a support matrix which provides an anchoring substratum for proliferation and/or differentiation of progenitor cells during tissue-specific morphogenesis.
Type:
Grant
Filed:
March 14, 1995
Date of Patent:
May 20, 2003
Assignee:
Curis, Inc.
Inventors:
Charles M. Cohen, Thangavel Kuberasampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger
Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
Type:
Grant
Filed:
October 13, 2000
Date of Patent:
April 22, 2003
Assignee:
Curis, Inc.
Inventors:
Anthony David Baxter, Edward Andrew Boyd, Oivin M. Guicherit, Stephen Price, Lee Rubin
Abstract: Disclosed are 1) amino acid sequence data, structural features, homologies and various other data characterizing morphogenic proteins, 2) methods of producing these proteins from natural and recombinant sources and from synthetic constructs, 3) morphogenic devices comprising these morphogenic proteins and a suitably modified tissue-specific matrix, and 4) methods of inducing non-chondrogenic tissue growth in a mammal.
Type:
Grant
Filed:
December 15, 1999
Date of Patent:
March 11, 2003
Assignee:
Curis, Inc.
Inventors:
Charles M. Cohen, Thangavel Kuberasampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger
Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.
Type:
Grant
Filed:
September 25, 1997
Date of Patent:
January 14, 2003
Assignee:
Curis, Inc.
Inventors:
David C. Rueger, Kuber T. Sampath, Charles M. Cohen, Hermann Oppermann, Roy H. L. Pang
Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects at risk chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain morphogens, inducers of those morphogens, or agonists of the corresponding morphogen receptors, or implantation of renal cells induced with those morphogens. The morphogens useful in the invention include osteogenic protein-1 (OP-1) and other members of the OP-1 subfamily of the TGF-&bgr; superfamily of growth factors.
Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.
Type:
Grant
Filed:
May 31, 1995
Date of Patent:
December 17, 2002
Assignee:
Curis, Inc.
Inventors:
David C. Rueger, Thangavel Kuberasampath, Hermann Oppermann, Engin Ozkaynak, Roy H. L. Pang, Charles M. Cohen
Abstract: A hedgehog conjugate which is characterized in that it contains: a) a polypeptide composed of 10 to 30 hydrophobic amino acids and/or amino acids which form transmembrane helices and are positively charged, b) 1 to 4 aliphatic, saturated or unsaturated hydrocarbon residues with a chain length of 10 to 24 C atoms and with a hydrophobic action or c) a hydrophobic thio compound covalently bound to a hedgehog protein and which has a several-fold increased activity and is suitable as a pharmaceutical agent.
Type:
Grant
Filed:
April 28, 1999
Date of Patent:
October 22, 2002
Assignee:
Curis, Inc.
Inventors:
Angelika Esswein, Kurt Lang, Petra Rueger, Tilman Seytter
Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.
Type:
Grant
Filed:
June 3, 1999
Date of Patent:
September 3, 2002
Assignees:
Curis, Inc., Biogen, Inc.
Inventors:
R. Blake Pepinsky, Darren P. Baker, Dingyi Wen, Kevin P. Williams, Ellen A. Garber, Frederick R. Taylor, Alphonse Galdes, Jeffrey Porter
Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here signalin-related genes, which are involved in signal transduction induced by members of the TGF&bgr; superfamily. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
Type:
Grant
Filed:
December 20, 1995
Date of Patent:
August 6, 2002
Assignee:
Curis, Inc.
Inventors:
Jonathan M. Graff, Tod M. Woolf, Ping Jin, Douglas A. Melton
Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of novel a transcriptional regulatory factor, referred to hereinafter as “Insulin Promoter Factor 1” or “Ipf1”.
Abstract: The invention relates to methods of preparing plasmid pools by growing colonies in discrete wells of a semi-solid or gelatinous medium. This method may facilitate colony collection, reduce colony overgrowth, reduce contamination by adventitious microorganisms, and increase the efficiency of plasmid screening techniques.
Abstract: The present invention provides methods and compositions for treatment of mammals afflicted with an ischemic or traumatic injury of the central nervous system. The present invention capitalizes in part upon the discovery that administration of a morphogen to such a mammal provides significant improvement in central nervous system function, even when administered after central nervous system tissue has been damaged. The methods involve the administration of dimeric proteins defined as morphogens, inducers of these morphogens, or agonists of the corresponding morphogen receptors, or implantation of cells stimulated by exposure to the morphogens. The proteins defined as morphogens comprise a structurally and functionally distinct family within the TGF-&bgr; superfamily. Osteogenic protein-1 (OP-1) is considered to be an exemplary and preferred member of this morphogen family.